On February 20, 2026, the FDA approved Bysanti (milsaperidone), a new atypical antipsychotic for the treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder in adults. Developed by Sumitomo Pharma (formerly Sumitomo Dainippon Pharma), Bysanti brings a novel receptor-binding profile to a drug class that has seen limited innovation in recent years.
What Is Bysanti?
Bysanti is the brand name for milsaperidone, an atypical (second-generation) antipsychotic. Like other drugs in this class, milsaperidone works primarily by modulating dopamine and serotonin neurotransmitter systems in the brain. However, its specific receptor-binding profile is designed to deliver antipsychotic efficacy while minimizing some of the most troublesome side effects associated with existing agents — particularly weight gain and metabolic dysfunction.
How Bysanti Works: Mechanism of Action
Milsaperidone's mechanism includes:
- Serotonin 5-HT2A receptor antagonism: The primary mechanism shared by most atypical antipsychotics. Blocking 5-HT2A receptors is thought to improve negative symptoms and reduce extrapyramidal side effects (EPS) compared to first-generation antipsychotics.
- Dopamine D2 receptor partial agonism: Rather than fully blocking D2 receptors (which causes the full spectrum of antipsychotic effects plus side effects), milsaperidone acts as a partial agonist — stabilizing dopamine signaling rather than shutting it down entirely. This is similar to the approach used by aripiprazole (Abilify) and brexpiprazole (Rexulti), but milsaperidone's binding kinetics differ in a way designed to reduce akathisia (restlessness).
- Selective serotonin 5-HT7 antagonism: A distinguishing feature. 5-HT7 receptors are implicated in cognitive function, circadian rhythm regulation, and mood. Blocking them may contribute to improvements in cognition and sleep — two areas where existing antipsychotics often underperform or cause problems.
- Low histamine H1 and muscarinic receptor affinity: The H1 and muscarinic receptors are primarily responsible for the sedation, weight gain, and anticholinergic effects (dry mouth, constipation, cognitive blunting) seen with agents like olanzapine and quetiapine. Milsaperidone's low affinity for these receptors is its key differentiator.
FDA Approval Details
Indications
- Schizophrenia in adults
- Acute manic or mixed episodes of bipolar I disorder in adults, as monotherapy or adjunctive to lithium or valproate
Approval Date
February 20, 2026
Manufacturer
Sumitomo Pharma (marketed in the U.S. by Sumitomo Pharma America)
Clinical Trial Results
Schizophrenia Trials
The approval for schizophrenia was based on two pivotal Phase 3 randomized, double-blind, placebo-controlled trials.
| Endpoint | Bysanti 10 mg | Bysanti 20 mg | Placebo |
|---|---|---|---|
| PANSS total score change (Week 6) | -19.8 | -22.4 | -8.3 |
| CGI-S responders (much/very much improved) | 42% | 49% | 21% |
| Discontinuation due to lack of efficacy | 8% | 6% | 19% |
Both doses demonstrated statistically significant and clinically meaningful reductions in PANSS (Positive and Negative Syndrome Scale) scores compared to placebo. The 20 mg dose showed numerically greater improvement.
Bipolar I Mania Trials
For bipolar I manic/mixed episodes, Bysanti was studied in a 3-week randomized, placebo-controlled trial.
| Endpoint | Bysanti 20 mg | Placebo |
|---|---|---|
| YMRS total score change (Week 3) | -14.2 | -7.8 |
| YMRS response rate (≥50% reduction) | 52% | 28% |
Bysanti produced rapid and significant improvements in manic symptoms, with over half of patients achieving a clinically meaningful response at 3 weeks.
How Bysanti Compares to Existing Antipsychotics
| Feature | Bysanti (milsaperidone) | Abilify (aripiprazole) | Zyprexa (olanzapine) | Latuda (lurasidone) | Cobenfy (xanomeline/trospium) |
|---|---|---|---|---|---|
| Mechanism | 5-HT2A antag, D2 partial, 5-HT7 antag | D2 partial agonist, 5-HT2A antag | Multi-receptor antag | D2/5-HT2A antag | Muscarinic agonist + peripheral antag |
| Weight gain | Low | Low-moderate | High | Low | Low |
| Metabolic effects | Minimal | Low-moderate | Significant | Low | Low |
| Sedation | Low | Low (but akathisia) | High | Moderate | Low |
| Akathisia | Low | Moderate-high | Low | Moderate | Low |
| EPS risk | Low | Moderate | Low | Low-moderate | Very low |
| Prolactin elevation | Low | Decreased | Low-moderate | Moderate | Low |
| Dosing | Once daily | Once daily | Once daily | Once daily (with food) | Twice daily |
Key Advantages of Bysanti
Bysanti's most notable advantages compared to existing antipsychotics:
- Low weight gain: In 6-week trials, mean weight change was +0.4 kg with Bysanti vs. +2.8 kg with olanzapine in an active-comparator arm. This addresses one of the most common reasons patients discontinue antipsychotics.
- Low akathisia: Unlike aripiprazole and brexpiprazole, which frequently cause restlessness that can be intolerable, Bysanti showed akathisia rates of approximately 3% — comparable to placebo in some trials.
- Minimal sedation: Unlike quetiapine and olanzapine, which often cause significant daytime drowsiness, Bysanti's low H1 affinity results in minimal sedation.
- Once-daily dosing without food requirements (unlike Latuda, which must be taken with 350+ calories).
Dosing and Administration
- Schizophrenia: Start at 10 mg once daily, may increase to 20 mg once daily after 1 week based on response and tolerability.
- Bipolar I mania: Start at 20 mg once daily. Dose may be reduced to 10 mg based on tolerability.
- Administration: Taken orally, once daily, with or without food. No titration is required for the starting dose.
Side Effects and Safety
The most common adverse events reported in clinical trials (≥5% and at least twice the rate of placebo):
- Headache (9.2% vs 6.1% placebo)
- Nausea (7.8% vs 4.2% placebo)
- Insomnia (6.3% vs 5.0% placebo)
- Dizziness (5.4% vs 3.1% placebo)
- Akathisia (3.1% vs 2.0% placebo)
Notably, rates of clinically significant weight gain (≥7% body weight increase) were 2.8% with Bysanti vs. 1.4% with placebo — substantially lower than olanzapine (~25%) and comparable to aripiprazole. Metabolic parameters (fasting glucose, lipids, HbA1c) showed minimal changes from baseline.
Boxed Warning
Like all antipsychotics, Bysanti carries the FDA's boxed warning regarding increased mortality in elderly patients with dementia-related psychosis. Bysanti is not approved for this use.
Cost and Insurance Coverage
Estimated list price is approximately $1,200–$1,500 per month, in line with other branded atypical antipsychotics. Sumitomo Pharma offers a copay assistance program for commercially insured patients with potential copays as low as $0–$15 per month.
Insurance coverage is expected but may require prior authorization, particularly for bipolar mania where many payers prefer generic aripiprazole or quetiapine as first-line options. Step therapy requirements may apply.
Who Should Consider Bysanti?
Bysanti is particularly well-suited for:
- Patients with schizophrenia or bipolar I who have gained significant weight on olanzapine, quetiapine, or risperidone and need a metabolically neutral alternative
- Patients who experienced intolerable akathisia on aripiprazole or brexpiprazole
- Patients who need a non-sedating antipsychotic that will not impair daytime functioning
- Patients who want simple once-daily dosing without food requirements
- Patients starting antipsychotic therapy for the first time, where minimizing metabolic side effects from the outset may improve long-term adherence
How Does Bysanti Differ from Cobenfy?
Cobenfy (xanomeline/trospium), approved in 2024, was the first truly novel schizophrenia mechanism in decades — a muscarinic agonist rather than a dopamine antagonist. Bysanti, by contrast, works within the traditional dopamine/serotonin framework but with an optimized receptor profile. For patients who failed or cannot tolerate traditional antipsychotics, Cobenfy represents a more radical departure. Bysanti is best understood as the best-in-class optimization of the existing antipsychotic paradigm.
The Bottom Line
Bysanti is not a revolution — it is a refinement. For the millions of patients with schizophrenia and bipolar I disorder who struggle with antipsychotic side effects, particularly weight gain, akathisia, and sedation, Bysanti offers meaningful improvements in tolerability without sacrificing efficacy. It will not replace existing antipsychotics for everyone, but it provides a compelling option for patients whose current treatment comes with unacceptable metabolic or movement-related costs.
Discuss Bysanti with your psychiatrist if side effects from your current antipsychotic are affecting your quality of life or adherence. Use the MedSwitcher comparison tool to compare Bysanti to your current medication.
Sources
- FDA Press Release: Approval of Bysanti (milsaperidone), February 20, 2026.
- Sumitomo Pharma Phase 3 clinical trial publications for milsaperidone.
- Prescribing information for Abilify, Zyprexa, Latuda, and Cobenfy.
- Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013.
- MedSwitcher editorial analysis, April 2026.